📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Brooks Labs Associate BSL Receives Stock Exchange NOC for Merger; Board to Review NCLT Filing
Brooks Laboratories Limited has provided an update regarding its associate company, Brooks Steriscience Limited (BSL), which is involved in a complex composite scheme of arrangement and amalgamation. BSL has received No-objection/No Adverse Observation Letters from both the NSE and BSE, marking a significant regulatory milestone. However, the BSL Board has decided to conduct a further review of the scheme before proceeding with the formal application to the National Company Law Tribunal (NCLT). This review is slated to be completed within the six-month validity period of the stock exchange approvals.
Key Highlights
BSL received No-objection letters from NSE and BSE for the proposed composite scheme of arrangement.
The stock exchange approvals are valid for a period of 6 months from the date of issue.
The scheme involves multiple entities including OneSource Specialty Pharma and Strides Pharma Services.
BSL Board has opted for a further internal review before filing the NCLT application.
The review process is expected to be finalized within the current six-month approval window.
💼 Action for Investors
Investors should track the progress of the BSL board's review and the subsequent NCLT filing, as this merger is a key value driver for Brooks' investment in the associate. The delay for 'further review' warrants a cautious watch on the final terms or potential adjustments to the scheme.
Brooks Labs Q3 Cons. PAT at ₹5.50 Cr; YoY Turnaround from Loss
Brooks Laboratories reported a consolidated net profit of ₹5.50 crore for Q3 FY26, marking a significant recovery from a loss of ₹2.13 crore in the previous year's corresponding quarter. This turnaround is largely attributed to a ₹5.20 crore profit contribution from its joint venture, Brooks Steriscience Limited. On a standalone basis, performance was subdued with revenue falling 19% YoY to ₹16.57 crore and net profit dropping to ₹0.30 crore. The company also faced a regulatory setback as the RoC did not approve the alteration of its Object Clause.
Key Highlights
Consolidated Net Profit of ₹5.50 crore in Q3 FY26 vs a loss of ₹2.13 crore in Q3 FY25
Joint venture Brooks Steriscience contributed ₹5.20 crore to the quarterly profit
Standalone Revenue declined 19.2% YoY to ₹16.57 crore from ₹20.52 crore
Nine-month consolidated profit stands at ₹23.06 crore compared to a loss of ₹8.51 crore last year
Regulatory rejection of Form MGT-14 prevents the planned alteration of the Memorandum of Association
💼 Action for Investors
While the consolidated turnaround is positive, the weakness in the core standalone business and the regulatory hurdle regarding the MoA amendment are concerns. Investors should monitor if the joint venture's profitability can consistently offset standalone sluggishness.